- Home
- ADPT vs XXI Comparison
ADPT vs XXI Comparison
Compare ADPT & XXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADPT | XXI |
|---|---|---|
| Founded | 2009 | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.2B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADPT | XXI |
|---|---|---|
| Price | $14.54 | $7.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $17.78 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 1.3M |
| Earning Date | 04-30-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $276,976,000.00 | N/A |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $22.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 54.77 | N/A |
| 52 Week Low | $6.77 | $5.61 |
| 52 Week High | $20.76 | $11.49 |
Technical Indicators
Market Signals| Indicator | ADPT | XXI |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 59.44 |
| Support Level | $12.19 | $5.66 |
| Resistance Level | $17.72 | $7.45 |
| Average True Range (ATR) | 0.99 | 0.39 |
| MACD | 0.14 | 0.08 |
| Stochastic Oscillator | 70.42 | 89.07 |
Price Performance
Historical ComparisonAbout ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.